Tag
Transcatheter tricuspid-valve repair plus medical therapy significantly improves survival, reduces heart failure hospitalizations, and enhances quality of life in patients with severe tricuspid regurgitation compared to medical therapy alon
This propensity-matched study shows that in patients undergoing tricuspid TEER for severe TR, untreated moderate MR is linked to worse survival, while combined mitral and tricuspid TEER improves mortality and functional outcomes, highlighti
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrenti
A study of 204 patients demonstrates that the GLIDE Score, originally for edge-to-edge repair, effectively predicts procedural success in transcatheter tricuspid valve annuloplasty (TTVA), with predictive accuracy further enhanced by incorp
A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic c
Transcatheter edge-to-edge repair (TEER) offers a safe, effective option to reduce tricuspid regurgitation severity, improve quality of life, and lower heart failure hospitalizations up to two years, including in patients with cardiac impla
